IRIS III研究：吡格列酮可改善2型糖尿病患者的代谢控制和血压，且不增加体重。 - Suppr

Suppr

超能文献

The IRIS III study: pioglitazone improves metabolic control and blood pressure in patients with type 2 diabetes without increasing body weight.

作者信息

Schöndorf T, Forst T, Hohberg C, Pahler S, Link C, Roth W, Pfützner A, Lübben G, Link C, Pfützner A

出版信息

Diabetes Obes Metab. 2007 Jan;9(1):132-3. doi: 10.1111/j.1463-1326.2006.00582.x.

DOI:10.1111/j.1463-1326.2006.00582.x

PMID:17199730

Abstract

摘要

相似文献

The IRIS III study: pioglitazone improves metabolic control and blood pressure in patients with type 2 diabetes without increasing body weight.IRIS III研究：吡格列酮可改善2型糖尿病患者的代谢控制和血压，且不增加体重。

Diabetes Obes Metab. 2007 Jan;9(1):132-3. doi: 10.1111/j.1463-1326.2006.00582.x.

[Pioglitazone effects on blood pressure in patients with metabolic syndrome].[吡格列酮对代谢综合征患者血压的影响]

Nihon Rinsho. 2008 Aug;66(8):1591-5.

Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial.吡格列酮对身体成分和能量消耗的影响：一项随机对照试验。

Metabolism. 2005 Jan;54(1):24-32. doi: 10.1016/j.metabol.2004.07.008.

Pioglitazone shift circadian rhythm of blood pressure from non-dipper to dipper type in type 2 diabetes mellitus.吡格列酮可使2型糖尿病患者的血压昼夜节律从非杓型转变为杓型。

Eur J Clin Invest. 2007 Sep;37(9):709-14. doi: 10.1111/j.1365-2362.2007.01854.x.

Inflammatory genes in epicardial fat contiguous with coronary atherosclerosis in the metabolic syndrome and type 2 diabetes: changes associated with pioglitazone.代谢综合征和 2 型糖尿病患者冠状动脉粥样硬化性心脏病相关心外膜脂肪中的炎症基因：与吡格列酮相关的变化。

Diabetes Care. 2011 Mar;34(3):730-3. doi: 10.2337/dc10-2083. Epub 2011 Feb 2.

Comparative effectiveness of pioglitazone and rosiglitazone in type 2 diabetes, prediabetes, and the metabolic syndrome: a meta-analysis.吡格列酮与罗格列酮在2型糖尿病、糖尿病前期及代谢综合征中的疗效比较：一项荟萃分析。

Curr Diabetes Rev. 2007 May;3(2):127-40. doi: 10.2174/157339907780598216.

Clinical trials with thiazolidinediones in subjects with Type 2 diabetes--is pioglitazone any different from rosiglitazone?噻唑烷二酮类药物用于2型糖尿病患者的临床试验——吡格列酮与罗格列酮有何不同？

Expert Opin Pharmacother. 2008 Feb;9(3):405-20. doi: 10.1517/14656566.9.3.405.

Comparison of metabolic profile and adiponectin level with pioglitazone versus voglibose in patients with type-2 diabetes mellitus associated with metabolic syndrome.比较吡格列酮与伏格列波糖治疗代谢综合征伴 2 型糖尿病患者的代谢特征和脂联素水平。

Endocr J. 2011;58(6):425-32. doi: 10.1507/endocrj.k10e-327. Epub 2011 Apr 17.

Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.恩格列净作为吡格列酮或吡格列酮加二甲双胍的附加疗法，可改善2型糖尿病患者的血糖和体重控制：一项为期24周的随机、安慰剂对照试验。

Diabetes Obes Metab. 2014 Feb;16(2):147-58. doi: 10.1111/dom.12188. Epub 2013 Aug 22.

Pharmacodynamic Effects of Low-Dose Pioglitazone in Patients with the Metabolic Syndrome without Diabetes Mellitus.低剂量吡格列酮对无糖尿病的代谢综合征患者的药效学作用

Pharmacotherapy. 2016 Mar;36(3):252-62. doi: 10.1002/phar.1713. Epub 2016 Feb 29.

引用本文的文献

Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug.重新思考吡格列酮作为心脏保护剂：一种被忽视药物的新视角。

Cardiovasc Diabetol. 2021 May 18;20(1):109. doi: 10.1186/s12933-021-01294-7.

Interplay between the renin-angiotensin system, the canonical WNT/β-catenin pathway and PPARγ in hypertension.肾素-血管紧张素系统、经典 WNT/β-连环蛋白通路和 PPARγ 在高血压中的相互作用。

Curr Hypertens Rep. 2018 Jun 9;20(7):62. doi: 10.1007/s11906-018-0860-4.

Nervous System Expression of PPARγ and Mutant PPARγ Has Profound Effects on Metabolic Regulation and Brain Development.PPARγ及突变型PPARγ在神经系统中的表达对代谢调节和脑发育具有深远影响。

Endocrinology. 2016 Nov;157(11):4266-4275. doi: 10.1210/en.2016-1524. Epub 2016 Aug 30.

Activation of central PPAR-γ attenuates angiotensin II-induced hypertension.中枢过氧化物酶体增殖物激活受体γ的激活可减轻血管紧张素II诱导的高血压。

Hypertension. 2015 Aug;66(2):403-11. doi: 10.1161/HYPERTENSIONAHA.115.05726. Epub 2015 Jun 22.

Sildenafil does not enhance but rather attenuates vasorelaxant effects of antidiabetic agents.西地那非不会增强而是会减弱抗糖尿病药物的血管舒张作用。

J Smooth Muscle Res. 2015;51:22-36. doi: 10.1540/jsmr.51.22.

Effect of pioglitazone and ramipril on biomarkers of low-grade inflammation and vascular function in nondiabetic patients with increased cardiovascular risk and an activated inflammation: results from the PIOace study.吡格列酮和雷米普利对心血管风险增加且炎症激活的非糖尿病患者低度炎症生物标志物和血管功能的影响：PIOace研究结果

J Diabetes Sci Technol. 2011 Jul 1;5(4):989-98. doi: 10.1177/193229681100500422.

A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes.盐酸吡格列酮与格列美脲治疗2型糖尿病的综述

Vasc Health Risk Manag. 2007;3(5):721-31.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验